Angiogenesis
is important for tumor growth, and accordingly, targeting
angiogenesis has become an important pathway for antitumor therapy.
A novel proapoptotic peptide, CIGB-300 (P15-Tat), has been shown to
be involved in the casein kinase II phosphorylation pathway, conferring
it with antiangiogenic activity. Cyclic peptides have been widely
used as scaffolds in drug design studies due to their high stability
and favorable biopharmaceutical properties. Here, we chose two very
stable cyclic trypsin inhibitors, MCoTI-II and SFTI-1, as frameworks
to incorporate the bioactive epitope P15 into various backbone loops.
NMR studies revealed that all re-engineered analogs had similar secondary
structures to their native cyclic frameworks. One key analog, MCoP15,
displayed significant improvement for inhibiting human umbilical vein
endothelial cell migration, was nontoxic, and had higher stability
than the P15 epitope alone. Overall, the results show the value of
P15 being engineered into cyclic trypsin inhibitor scaffolds for improving
antiangiogenic activity and stability. More broadly, the study highlights
the versatility of cyclic peptide frameworks in drug design for antiangiogenic
therapies.